Insys Therapeutics (INSY) Misses Q3 EPS by 6c, Miss on Revenues

Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $30.67 million versus the consensus estimate of $36.69 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• Capitol Federal Financial names William Skrobacz Jr. as president
• KB Home (KBH) Tops Q3 EPS by 16c